Julie B. Kampf Among Women of Influence Recognized by New York Business Journal

Englewood Cliffs, N.J./December 16, 2015 – Julie B. Kampf, CEO & Chief Possibilities Officer of the executive talent solutions firm JBK Associates International, has been named one of New York Business Journal’s 2016 Women of Influence Award honorees.  Kampf is among 79 New York metropolitan area business leaders recognized as women who innovate, succeed and… Read the full article



Celator® Pharmaceuticals Presents Positive Results from R&D Programs

  EWING, N.J., Nov. 10, 2015 — Celator Pharmaceuticals, Inc. announced the presentation of positive results from its CombiPlex® technology platform applied to drug combinations incorporating molecularly targeted agents (MTAs) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. CombiPlex is Celator’s proprietary technology that uses nano-scale drug carriers to ensure the optimal… Read the full article


Rowan University Announce Blood-based Biomarkers for Early Detection, Diagnosis and Staging of Parkinson’s Disease

Researchers Announce Blood-based Biomarkers for Early Detection, Diagnosis and Staging of Parkinson’s Disease STRATFORD – In a study involving nearly 400 subjects, researchers from the Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., have demonstrated that a blood test they developed can detect early-stage Parkinson’s disease. Using human protein microarrays, the researchers identified… Read the full article


Celator® Pharmaceuticals Announces VYXEOS™ (CPX -351) Shows No QT/QTc Interval Prolongation in an Intensive QT/QTc Study

Accepted for presentation at the upcoming American Society of Hematology (ASH) Annual Meeting EWING, N.J., Oct. 21, 2015 — Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that a Phase 2 pharmacokinetic and pharmacodynamics (PK/PD) study evaluating the effects of VYXEOS™ (CP-X351) on cardiac depolarization/repolarization has concluded and VYXEOS did not prolong the QT/QTc interval. This… Read the full article


NDRI commemorates 35-year history, envisions advances of human tissue research

Philadelphia, October 20, 2015 — Philadelphia-based National Disease Research Interchange (NDRI), the nation’s premier provider of human biospecimens to advance medical disease research, will host a symposium, “From Donation to Discovery — The Critical Role of Human Tissue in Research,” Friday, October 30 at The Union League of Philadelphia. The event marks NDRI’s 35th anniversary… Read the full article


Celator® Pharmaceuticals Announces Positive Recommendation From Data And Safety Monitoring Board For Phase 3 Study Of CPX-351

Celator® Pharmaceuticals Announces Positive Recommendation From Data And Safety Monitoring Board For Phase 3 Study Of CPX-351 (VYXEOS™) – Company expects Overall Survival Data in First Quarter of 2016 – EWING, N.J., Oct. 19, 2015 /PRNewswire/ — Celator Pharmaceuticals, Inc. (NASDAQ: CPXX) today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company’s Phase 3… Read the full article


Grünenthal USA Celebrates Opening of New Office in Morristown

Grünenthal USA celebrates opening of new office in Morristown October 7, 2015 Grünenthal USA, Inc. recently celebrated the opening of its new office space in Morristown, New Jersey.  Executive board members including Alberto Grua, Chief Commercial Officer, and Klaus Langner, Chief Scientific Officer, from Grünenthal GmbH joined local CEO, Sascha Mielcarek during the ribbon cutting… Read the full article


Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment

Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment Co-recipient Dr. William C. Campbell Conducted his Nobel Prize-winning Work at Merck Research Laboratories KENILWORTH, N.J., Oct. 5, 2015 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, proudly congratulates William C. Campbell,… Read the full article


Edge Therapeutics Announces Pricing of its Initial Public Offering

Edge Therapeutics Announces Pricing of its Initial Public Offering Berkeley Heights, NJ – September 30, 2015 – Edge Therapeutics, Inc. today announced the pricing of its initial public offering of 7,315,151 shares of its common stock at a public offering price of $11.00 per share, before underwriting discounts and commissions. All of the shares of… Read the full article